Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907140 | 0.86 | KMT2A (0.53) | NPC1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL26793959 | 0.86 | KMT2A (0.53) | NPC1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL5248286 | 0.84 | MAPK1 (0.56) | KMT2AMAPTALDH1A1POLBKDM4E | |
| SCHEMBL474024 | 0.83 | KMT2A (0.51) | NPC1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL17275525 | 0.83 | NPC1 (0.53) | NPC1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL1279177 | 0.82 | KMT2A (0.46) | NPC1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL25117833 | 0.81 | KMT2A (0.49) | NPC1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL30317187 | 0.81 | KMT2A (0.49) | NPC1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL2248162 | 0.81 | KMT2A (0.52) | NPC1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL14609680 | 0.81 | KMT2A (0.49) | NPC1KMT2AMAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350073-B1 | 3H-IMIDAZO[4,5-b]PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-8703796-B2 | 3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| EP-1940837-B1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2350073-A1 | 3H-IMIDAZO[4,5-b]PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010034799-A1 | 3H-IMIDAZ0 [4, 5-B] PYRIDINE- 6 -CARBOXAMIDES AS ANTI -INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-6890934-B2 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6573274-B1 | Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | NPC1 3486/4885KMT2A 2502/4885MAPT 3003/4885 |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | NPC1 4449/4885KMT2A 1218/4885MAPT 4591/4885 |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | PDE2A, PDE3A, PDE5A | NPC1 4422/4885KMT2A 1625/4885MAPT 4144/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | NPC1 4845/4885KMT2A 1587/4885MAPT 4725/4885 |
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | MAP4, MAPRE2, IL4 | NPC1 4771/4885KMT2A 992/4885MAPT 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.